Showing 1 - 4 results of 4 for search 'Andrew D. Chantry', query time: 0.03s Refine Results
  1. 1
    Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.

    Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. by Srdjan Vitovski, Andrew D Chantry, Michelle A Lawson, Peter I Croucher

    Published 2012-01-01
    Get full text
    Article
  2. 2
    ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.

    ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. by Darren L Lath, Clive H Buckle, Holly R Evans, Matthew Fisher, Jenny M Down, Michelle A Lawson, Andrew D Chantry

    Published 2018-01-01
    Get full text
    Article
  3. 3
    HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib <i>In Vitro</i> and Significantly Reduces Systemic Tumor Growth in Mouse Models

    HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib <i>In Vitro</i> and Significantly Reduces Systemic Tumor Growth in Mouse Models by Simon Tazzyman, Georgia R. Stewart, James Yeomans, Adam Linford, Darren Lath, Joe Conner, Munitta Muthana, Andrew D. Chantry, Michelle A. Lawson

    Published 2023-02-01
    Get full text
    Article
  4. 4
    Low-dose methotrexate in myeloproliferative neoplasm models

    Low-dose methotrexate in myeloproliferative neoplasm models by Kavitha Chinnaiya, Michelle A. Lawson, Sally Thomas, Marie-Therese Haider, Jenny Down, Andrew D. Chantry, David Hughes, Antony Green, Jon R. Sayers, John A. Snowden, Martin P. Zeidler

    Published 2017-09-01
    Get full text
    Article

Search Tools: